UK-wide licensing for human medicines

AI Summary

This guidance document details the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) implementation of licensing changes for human medicines following the Windsor Framework. Under this regulatory framework, the MHRA assumes full responsibility for medicinal authorizations across the entire United Kingdom starting January 1, 2025. This transition resolves previous issues regarding regulatory divergence between Great Britain and Northern Ireland. As this is a general policy guidance, specific company names and inspection dates are not applicable. The core regulatory issues addressed involve the shift from European Medicines Agency (EMA) oversight in Northern Ireland to a unified UK-wide system. Required actions for industry stakeholders include updating product packaging to include mandatory 'UK Only' labels by the 2025 deadline and ensuring all marketing authorizations are processed through the MHRA. Manufacturers must also adhere to new notification procedures for category-specific medicines to maintain lawful market access. By following these steps, companies ensure continued compliance with UK law while facilitating the equal distribution of medicines across all UK territories, thereby streamlining the administrative burden previously caused by dual-regulatory requirements.